Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

4.33
-0.1100-2.48%
Volume:78.81K
Turnover:349.55K
Market Cap:65.05M
PE:-0.89
High:4.60
Open:4.55
Low:4.28
Close:4.44
Loading ...

Jasper Therapeutics Inc - 100% Complete Responses in 240Mg Cohort at 8 Weeks

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Reports Positive Data From Beacon Study of Briquilimab in Chronic Spontaneous Urticaria

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

GlobeNewswire
·
08 Jan

Jasper Therapeutics: Promising Growth Potential in the Urticaria Market with Briquilimab’s Emerging Efficacy Profile

TIPRANKS
·
07 Jan

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

GlobeNewswire
·
06 Jan

Jasper Therapeutics Positioned for Success in Urticaria Market with Upcoming Briquilimab Data

TIPRANKS
·
06 Jan

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
04 Jan

Analysts Are Bullish on These Healthcare Stocks: Jasper Therapeutics (JSPR), Celldex (CLDX)

TIPRANKS
·
02 Jan

Jasper Therapeutics Price Target Maintained With a $68.00/Share by RBC Capital

Dow Jones
·
23 Dec 2024

Analysts Conflicted on These Healthcare Names: Neurocrine (NBIX), Vertex Pharmaceuticals (VRTX) and Jasper Therapeutics (JSPR)

TIPRANKS
·
23 Dec 2024

Jasper Therapeutics initiated with an Outperform at BMO Capital

TIPRANKS
·
06 Dec 2024

BRIEF-Jasper Therapeutics Announces First Patient Dosed In Phase 1B/2A Etesian Clinical Study

Reuters
·
03 Dec 2024

Jasper Therapeutics Inc - Initial Data Expected in Second Half of 2025

THOMSON REUTERS
·
03 Dec 2024

Jasper Therapeutics Announces First Patient Dosed in Phase 1B/2a Etesian Clinical Study of Briquilimab in Asthma

THOMSON REUTERS
·
03 Dec 2024

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

GlobeNewswire
·
03 Dec 2024

Jasper Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire
·
14 Nov 2024

Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise

GuruFocus.com
·
09 Nov 2024

Strong Buy Rating for Jasper Therapeutics Driven by Promising Briquilimab Developments and Solid Cash Position

TIPRANKS
·
08 Nov 2024

Jasper Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
07 Nov 2024

Jasper Therapeutics Q3 2024 GAAP EPS $(1.24) Misses $(1.08) Estimate

Benzinga
·
07 Nov 2024